Economia · ArchivioNovo Nordisk Sues Eli Lilly Over Allegedly Misleading GLP-1 AdsScritto 7 settembre 2026 alle ore 21:22 UTCGuardaTrascrizione0:00The weight loss drug war has moved from0:01the pharmacy counter to federal court.0:03Novo Nordisk has filed a lawsuit against0:05Eli Lilly accusing the American0:07pharmaceutical giant of running false0:09and misleading advertisements for its0:11blockbuster GLP-1 weight loss and0:12diabetes drugs.0:15At the heart of the case are what Novo0:16calls unfair dosing comparisons,0:18allegations that Lilly's ads compare0:20higher doses of its own drugs against0:22lower doses of Novo's while leaving out0:24newer higher dose options that compete0:25more directly. Novo Nordisk,0:27headquartered in Copenhagen, makes0:29Wegovy and Ozempic. Eli Lilly, based in0:32Indianapolis, makes Zepbound and0:34Mounjaro. The lawsuit was filed in the0:36District of New Jersey, escalating what0:38is already a fierce rivalry in the0:40nearly $150 billion GLP-1 market.0:43Specifically, Novo alleges that Lilly's0:46direct-to-consumer advertising compares0:48higher doses of Mounjaro and Zepbound0:50against lower doses of Ozempic and0:51Wegovy while omitting Novo's newer and0:54more directly comparable higher dose0:55options, potentially misleading patients0:57and healthcare providers. On the Novo0:59side, Wegovy for weight loss and Ozempic1:02for diabetes. On the Lilly side,1:04Zepbound for weight loss and Mounjaro1:06for diabetes. Collectively, these four1:08drugs dominate a market that has1:10reshaped the pharmaceutical industry.1:12Lilly has pushed back, defending its1:14advertisements as truthful and based on1:16the best available scientific evidence.1:18The company says the dosing comparisons1:20are accurate and supported by clinical1:21data. This lawsuit is the latest chapter1:24in intensifying competition between two1:26pharmaceutical giants, a battle that1:27shows no signs of cooling as the GLP-11:30market continues to explode.Leggi l’articoloCronologia della storiaHeyDexIl video breve ↗
